Biotech

All Articles

Ideaya bags possibility on Biocytogen bispecific ADC in $400M bargain

.Ideaya Biosciences is wagering $400 million in biobucks that a bispecific antibody-drug conjugate (...

Takeda takes $140M reduction on failed epilepsy medicine, boasts FDA manage

.We already know that Takeda is planning to locate a road to the FDA for epilepsy medication soticle...

VBI Injections files for personal bankruptcy, looks for possession sale

.Immunology biotech VBI Injections is actually diverting alarmingly near the point of no return, wit...

Celldex anti-cKIT antitoxin lower colonies in another phase 2 research study

.It is actually hard to muscle in on a space as very competitive as immunology, yet Celldex Therapeu...

Boehringer provides to $1.3 B for checkpoint inhibitor biotech

.Boehringer Ingelheim is actually providing to $1.3 billion for Nerio Rehabs as well as a preclinica...

Ventyx's last resort for inflammatory med ends in Crohn's failure

.Ventyx Biosciences' Crohn's ailment medication carried out certainly not assist individuals obtain ...

Cognition's period 2 beam information stain Alzheimer's prospect

.Cognition Therapeutics' stage 2 luster test has taken a number of the radiance off the Alzheimer's ...

BMS centers bispecific months after filing to function stage 3 trial

.Bristol Myers Squibb has actually possessed a whiplash change of heart on its own BCMA bispecific T...

Charles Baum manages Terremoto as CEO

.Charles Baum, M.D., Ph.D., who managed Mirati Therapeutics' $ 5.8 billion purchase to Bristol Myers...

Asarina to shut after initiatives to partner Tourette's drug neglect

.After reaching out to much more than 200 business to companion a Tourette syndrome therapy that pre...